Skip to content
ppharmaranks
Menu

MVASI vs VIZIMPRO

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 20, 2026·How we rate

Possible drug interaction. MVASI and VIZIMPRO are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Rating

72/100
64/100

Pharmacy pays

Type

RX
RX

Active ingredient

BEVACIZUMAB-AWWB
DACOMITINIB

Manufacturer

Dosage forms

Injectable
Tablet

Drug class

Boxed warning

None
None

Treats

Non-Small-Cell Lung Carcinoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms
Non-Small-Cell Lung Carcinoma

Frequently asked questions

Which is better-rated, Mvasi or Vizimpro?

By our independent rating, Mvasi scores higher — 3.6 vs 3.2 out of 5 for Vizimpro. Ratings are based on FDA regulatory (recall-safety) data.

What is the difference between Mvasi and Vizimpro?

Mvasi contains Bevacizumab-Awwb, while Vizimpro contains Dacomitinib — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.